Published in J Invest Dermatol on May 10, 2007
Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. Eur J Health Econ (2014) 0.88
Why are quality of life instruments not recognized as reference measures in therapeutic trials of chronic skin disorders? J Invest Dermatol (2007) 0.87
Exploring differential item functioning in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). BMC Musculoskelet Disord (2012) 0.84
Psoriasis: correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment. An Bras Dermatol (2013) 0.84
Quality of life in patients with skin diseases in central Saudi Arabia. Int J Gen Med (2012) 0.78
Adaptation of the osteoarthritis-specific quality of life scale (the OAQoL) for use in Germany, Hungary, Italy, Spain and Turkey. Rheumatol Int (2017) 0.76
Rasch analysis holds no brief for the use of the Dermatology Life Quality Index (DLQI) in Chinese neurodermatitis patients. Health Qual Life Outcomes (2016) 0.75
Adaptation of the QoL-AGHDA scale for adults with growth hormone deficiency in four Slavic languages. Health Qual Life Outcomes (2011) 0.75
Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol (2006) 4.12
Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J (2009) 3.93
Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. BMJ (2013) 3.22
Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med (2012) 3.14
The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol (2008) 2.95
The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol (2010) 2.90
Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis? J Invest Dermatol (2011) 2.37
Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol (2011) 2.36
National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol (2007) 2.29
Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol (2010) 2.29
Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol (2008) 2.25
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol (2008) 2.19
Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology (2005) 2.15
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol (2011) 2.03
Interpretation of Skindex-29 scores: cutoffs for mild, moderate, and severe impairment of health-related quality of life. J Invest Dermatol (2011) 2.02
Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med (2011) 1.94
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol (2009) 1.94
Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol (2013) 1.88
Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol (2005) 1.88
Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol (2011) 1.88
Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol (2008) 1.80
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol (2009) 1.76
Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol (2013) 1.64
Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis (2012) 1.63
The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol (2011) 1.59
AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol (2008) 1.54
Major cardiovascular events associated with anti-IL 12/23 agents: a tale of two meta-analyses. J Am Acad Dermatol (2013) 1.49
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol (2009) 1.48
Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol (2012) 1.46
Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repigmenting vitiligo. Arch Dermatol (2004) 1.39
Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol (2012) 1.37
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol (2007) 1.35
Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis (2012) 1.29
United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transplant (2008) 1.26
S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges (2012) 1.25
Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol (2012) 1.21
Complexity of the association between psoriasis and comorbidities. J Invest Dermatol (2009) 1.19
Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients. J Am Acad Dermatol (2011) 1.18
Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Am Acad Dermatol (2005) 1.16
Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology (Oxford) (2012) 1.15
Sensitivity, specificity, and diagnostic accuracy of three dermoscopic algorithmic methods in the diagnosis of doubtful melanocytic lesions: the importance of light brown structureless areas in differentiating atypical melanocytic nevi from thin melanomas. J Am Acad Dermatol (2007) 1.13
Effect of axillary lymph node dissection on prevalence and intensity of chronic and phantom pain after breast cancer surgery. J Pain (2008) 1.12
Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology (Oxford) (2013) 1.11
Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays. Cancer Res (2009) 1.10
Origin, clinical presentation, and diagnosis of hypomelanotic skin disorders. Dermatol Clin (2007) 1.10
Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol (2012) 1.09
Health-related quality of life assessment in dermatology: interpretation of Skindex-29 scores using patient-based anchors. J Invest Dermatol (2009) 1.09
Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. Ann Rheum Dis (2012) 1.08
The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol (2009) 1.07
Consensus guidelines for the management of plaque psoriasis. Arch Dermatol (2012) 1.06
Update on the epidemiology and systemic treatment of psoriasis. Expert Rev Clin Immunol (2007) 1.05
Effects of method of translation of patient-reported health outcome questionnaires: a randomized study of the translation of the Rheumatoid Arthritis Quality of Life (RAQoL) Instrument for Sweden. Value Health (2009) 1.04
Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network. Pharmacoepidemiol Drug Saf (2014) 1.04
Prevalence and associated factors of betapapillomavirus infections in individuals without cutaneous squamous cell carcinoma. J Gen Virol (2009) 1.04
Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol (2005) 1.03
Requirements for quality of life instruments in clinical research. Value Health (2004) 1.03
Satisfaction of patients after treatment with botulinum toxin for dynamic facial lines. Dermatol Surg (2003) 1.01
Long-term treatment for severe psoriasis: we're halfway there, with a long way to go. Arch Dermatol (2007) 1.00
Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol (2009) 1.00
HIV-positive patients in Botswana state that mobile teledermatology is an acceptable method for receiving dermatology care. J Telemed Telecare (2011) 1.00
Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009. Pharmacoepidemiol Drug Saf (2013) 1.00
Testing and reducing skindex-29 using Rasch analysis: Skindex-17. J Invest Dermatol (2006) 0.99
Categorization of Skindex-29 scores using mixture analysis. Dermatology (2008) 0.99
Multivariate analyses of patient financial systems and oral health-related quality of life. Community Dent Oral Epidemiol (2010) 0.98
Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses. Health Qual Life Outcomes (2008) 0.98
Early life factors related to clinical manifestations of atopic disease but not to skin-prick test positivity in young children. Pediatr Allergy Immunol (2002) 0.98
Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12. Clin Lymphoma Myeloma (2007) 0.97
Antibody responses to 26 skin human papillomavirus types in the Netherlands, Italy and Australia. J Gen Virol (2009) 0.97
Subjective and objective evaluation of noncultured epidermal cellular grafting for repigmenting vitiligo. Dermatology (2006) 0.97
Methicillin-resistant Staphylococcus aureus colonization in children with atopic dermatitis. Pediatr Dermatol (2008) 0.96
Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges (2005) 0.96
[S3-guidelines for the treatment of psoriasis vulgaris Update 2011]. J Dtsch Dermatol Ges (2011) 0.96
Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther (2009) 0.96
Surrogate end points for the treatment of diabetic neuropathic foot ulcers. Diabetes Care (2003) 0.96
Update on the natural history and systemic treatment of psoriasis. Adv Dermatol (2008) 0.96
Quality-of-life assessment in patients with pemphigus using a minimum set of evaluation tools. J Am Acad Dermatol (2008) 0.96
Adverse cutaneous reactions to guggulipid. J Am Acad Dermatol (2005) 0.95
Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). J Vis Exp (2012) 0.93
Dermatologist response rates to a mailed questionnaire: a randomized trial of monetary incentives. J Am Acad Dermatol (2011) 0.93
A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol (2009) 0.93
International development of the patient-reported outcome indices for multiple sclerosis (PRIMUS). Value Health (2010) 0.93
A new digital image analysis system useful for surface assessment of vitiligo lesions in transplantation studies. Eur J Dermatol (2004) 0.92
Self-inflicted lesions in dermatology: terminology and classification--a position paper from the European Society for Dermatology and Psychiatry (ESDaP). Acta Derm Venereol (2013) 0.92
The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol (2010) 0.92
The epidemiology of sunburn in the US population in 2003. J Am Acad Dermatol (2006) 0.92
Health-related quality of life in patients with cutaneous rosacea: a systematic review. Acta Derm Venereol (2015) 0.92
Cost-of-illness of chronic leg ulcers in Germany. Int Wound J (2010) 0.92
Perioperative stress response to carotid endarterectomy: the impact of anesthetic modality. J Vasc Surg (2004) 0.91
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol (2012) 0.91
Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial. J Am Acad Dermatol (2008) 0.91
The epidemiology of atopic dermatitis. Clin Dermatol (2003) 0.91
Seeing red: flushing out instigators of niacin-associated skin toxicity. J Clin Invest (2010) 0.91
Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges (2007) 0.90
High prevalence of aquagenic wrinkling of the palms in patients with cystic fibrosis and association with measurable increases in transepidermal water loss. Pediatr Dermatol (2012) 0.90
Testing a workplace physical activity intervention: a cluster randomized controlled trial. Int J Behav Nutr Phys Act (2011) 0.90
Nail psoriasis - a treatment challenge. J Dtsch Dermatol Ges (2013) 0.89
Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian. Can Respir J (2008) 0.89
Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol (2013) 0.89
Identification of risk factors for psoriatic arthritis: scientific opportunity meets clinical need. Arch Dermatol (2010) 0.89